Menu
GeneBe

rs33963999

Variant summary

Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP2BA1

This summary comes from the ClinGen Evidence Repository: The NM_004360.5(CDH1):c.531+10G>C variant has an allele frequency of 0.05787 (5.787%, 1453/25106 alleles, 39 homozygotes) in the African subpopulation of the gnomAD v2.1.1 cohort (BA1; BP2). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BP2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA169542/MONDO:0007648/007

Frequency

Genomes: 𝑓 0.038 ( 175 hom., cov: 32)
Exomes 𝑓: 0.054 ( 2440 hom. )

Consequence

CDH1
NM_004360.5 intron

Scores

2

Clinical Significance

Benign reviewed by expert panel B:15

Conservation

PhyloP100: 0.855
Variant links:
Genes affected
CDH1 (HGNC:1748): (cadherin 1) This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function of this gene is thought to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. This gene is present in a gene cluster with other members of the cadherin family on chromosome 16. [provided by RefSeq, Nov 2015]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -9 ACMG points.

BP2
BA1

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CDH1NM_004360.5 linkuse as main transcriptc.531+10G>C intron_variant ENST00000261769.10
CDH1NM_001317184.2 linkuse as main transcriptc.531+10G>C intron_variant
CDH1NM_001317185.2 linkuse as main transcriptc.-1085+10G>C intron_variant
CDH1NM_001317186.2 linkuse as main transcriptc.-1289+10G>C intron_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CDH1ENST00000261769.10 linkuse as main transcriptc.531+10G>C intron_variant 1 NM_004360.5 P1P12830-1

Frequencies

GnomAD3 genomes
AF:
0.0380
AC:
5790
AN:
152172
Hom.:
174
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0104
Gnomad AMI
AF:
0.0186
Gnomad AMR
AF:
0.0320
Gnomad ASJ
AF:
0.0435
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.0170
Gnomad FIN
AF:
0.0536
Gnomad MID
AF:
0.0411
Gnomad NFE
AF:
0.0580
Gnomad OTH
AF:
0.0430
GnomAD3 exomes
AF:
0.0385
AC:
9672
AN:
251068
Hom.:
254
AF XY:
0.0391
AC XY:
5312
AN XY:
135756
show subpopulations
Gnomad AFR exome
AF:
0.00910
Gnomad AMR exome
AF:
0.0218
Gnomad ASJ exome
AF:
0.0399
Gnomad EAS exome
AF:
0.000436
Gnomad SAS exome
AF:
0.0214
Gnomad FIN exome
AF:
0.0586
Gnomad NFE exome
AF:
0.0546
Gnomad OTH exome
AF:
0.0389
GnomAD4 exome
AF:
0.0538
AC:
78655
AN:
1461656
Hom.:
2440
Cov.:
33
AF XY:
0.0527
AC XY:
38312
AN XY:
727122
show subpopulations
Gnomad4 AFR exome
AF:
0.00833
Gnomad4 AMR exome
AF:
0.0237
Gnomad4 ASJ exome
AF:
0.0396
Gnomad4 EAS exome
AF:
0.000202
Gnomad4 SAS exome
AF:
0.0216
Gnomad4 FIN exome
AF:
0.0600
Gnomad4 NFE exome
AF:
0.0612
Gnomad4 OTH exome
AF:
0.0493
GnomAD4 genome
AF:
0.0380
AC:
5792
AN:
152290
Hom.:
175
Cov.:
32
AF XY:
0.0381
AC XY:
2840
AN XY:
74464
show subpopulations
Gnomad4 AFR
AF:
0.0104
Gnomad4 AMR
AF:
0.0319
Gnomad4 ASJ
AF:
0.0435
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.0172
Gnomad4 FIN
AF:
0.0536
Gnomad4 NFE
AF:
0.0581
Gnomad4 OTH
AF:
0.0425
Alfa
AF:
0.0492
Hom.:
49
Bravo
AF:
0.0343
Asia WGS
AF:
0.00982
AC:
34
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:15
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:6
Benign, no assertion criteria providedclinical testingMayo Clinic Laboratories, Mayo Clinic-- -
Benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Benign, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalAug 15, 2023- -
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact Sciences-- -
Benign, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, University Medical Center Utrecht-- -
Benign, no assertion criteria providedclinical testingClinical Genetics, Academic Medical Center-- -
not provided Benign:2
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 22, 2023- -
Benign, criteria provided, single submitterclinical testingGeneDxMar 03, 2015- -
Hereditary diffuse gastric adenocarcinoma Benign:2
Benign, criteria provided, single submitterclinical testingInvitaeFeb 01, 2024- -
Benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 13, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthDec 10, 2014- -
Benign, criteria provided, single submitterclinical testingAmbry GeneticsNov 18, 2014This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Malignant tumor of breast Benign:1
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-CDH1, EXON4, c.531+10G>C, p.?, Heterozygous, BenignrnThe CDH1 c.531+10G>C variant was identified in 7 of 194 proband chromosomes (frequency: 0.036) from individuals or families with gastric cancer and colorectal cancer, but the variant was classified as a benign polymorphism in these studies (Berx 1997, Oliveira 2002, Verma 2001). The variant was also identified in dbSNP (rs: rs33963999) as other, ClinVar 5x (classified as benign by multiple submitters), and the Zhejiang Colon Cancer Database (3x). The variant was not identified in Cosmic, MutDB, or Insight Colon Cancer Gene Variant Database. The variant was identified in control databases in 10752 of 276938 chromosomes at a frequency of 0.0388 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017). The variant was identified in the following populations at a frequency greater than 1%: European (Finnish) in 1496 (42 homozygous) of 25776 chromosomes (freq: 0.058), European (Non-Finnish) in 6956 (196 homozygous) of 126510 chromosomes (freq: 0.055), Ashkenazi Jewish* in 404 (11 homozygous) of 10146 chromosomes (freq: 0.04), Other in 245 (8 homozygous) of 6458 chromosomes (freq: 0.038), Latino in 750 (13 homozygous) of 34410 chromosomes (freq: 0.022), South Asian in 665 (12 homozygous) of 30780 chromosomes (freq: 0.022). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -
Malignant tumor of prostate Benign:1
Benign, criteria provided, single submitterclinical testingKCCC/NGS Laboratory, Kuwait Cancer Control CenterJul 07, 2023- -
CDH1-related diffuse gastric and lobular breast cancer syndrome Benign:1
Benign, reviewed by expert panelcurationClinGen CDH1 Variant Curation Expert PanelAug 10, 2023The NM_004360.5(CDH1):c.531+10G>C variant has an allele frequency of 0.05787 (5.787%, 1453/25106 alleles, 39 homozygotes) in the African subpopulation of the gnomAD v2.1.1 cohort (BA1; BP2). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BP2. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.80
CADD
Benign
13
DANN
Benign
0.55

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs33963999; hg19: chr16-68842480; COSMIC: COSV55728473; COSMIC: COSV55728473; API